Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Thibaudin

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|June 9, 2021
Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacyJulie Niogret, Hélène Berger, Cédric Rebe, et al.
The Journal of Clinical Investigation|July 1, 2025
Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doubletLaura Kalfeist, Fanny Ledys, Stacy Petit, et al.
Signal Transduction and Targeted Therapy|January 17, 2025
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trialMarion Thibaudin, Nicolas Roussot, Chloé Burlot, et al.
Journal for Immunotherapy of Cancer|June 22, 2026
IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapyMannon Geindreau, Cassandre Pignol, Loïs Coënon, et al.
Future Oncology (London, England)|November 12, 2024
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancerJean-David Fumet, Nicolas Roussot, Aurélie Bertaut, et al.
Cancer Immunology Research|May 25, 2022
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor EffectsRomain Mary, Fanny Chalmin, Théo Accogli, et al.
Cancers|June 4, 2020
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal CarcinomaJulie Niogret, Emeric Limagne, Marion Thibaudin, et al.
Nature Medicine|August 10, 2023
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trialMarion Thibaudin, Jean-David Fumet, Benoist Chibaudel, et al.
Frontiers in Immunology|August 22, 2024
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, <i>KEAP1/STK11</i> co-mutated metastatic NSCLCNicolas Roussot, Marion Thibaudin, Jean-David Fumet, et al.
BMC Cancer|November 10, 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancerNicolas Roussot, Jean-David Fumet, Emeric Limagne, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|June 9, 2021
Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacyJulie Niogret, Hélène Berger, Cédric Rebe, et al.
The Journal of Clinical Investigation|July 1, 2025
Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doubletLaura Kalfeist, Fanny Ledys, Stacy Petit, et al.
Signal Transduction and Targeted Therapy|January 17, 2025
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trialMarion Thibaudin, Nicolas Roussot, Chloé Burlot, et al.
Journal for Immunotherapy of Cancer|June 22, 2026
IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapyMannon Geindreau, Cassandre Pignol, Loïs Coënon, et al.
Future Oncology (London, England)|November 12, 2024
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancerJean-David Fumet, Nicolas Roussot, Aurélie Bertaut, et al.
Cancer Immunology Research|May 25, 2022
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor EffectsRomain Mary, Fanny Chalmin, Théo Accogli, et al.
Cancers|June 4, 2020
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal CarcinomaJulie Niogret, Emeric Limagne, Marion Thibaudin, et al.
Nature Medicine|August 10, 2023
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trialMarion Thibaudin, Jean-David Fumet, Benoist Chibaudel, et al.
Frontiers in Immunology|August 22, 2024
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, <i>KEAP1/STK11</i> co-mutated metastatic NSCLCNicolas Roussot, Marion Thibaudin, Jean-David Fumet, et al.
BMC Cancer|November 10, 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancerNicolas Roussot, Jean-David Fumet, Emeric Limagne, et al.
Pageof 4